Marché mondial du syndrome d’excès d’aromatase – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché                              

Le syndrome d'excès d'aromatase est un trouble dans lequel les hommes et les femmes présentent des niveaux excessifs d'œstrogène, une hormone sexuelle féminine. À la fin de la petite enfance ou à l'adolescence, les hommes atteints du syndrome d'excès d'aromatase développent une croissance mammaire (gynécomastie). Les os des hommes affectés grandissent et mûrissent plus rapidement et cessent de se développer plus tôt que la normale (âge osseux avancé). En conséquence, les garçons connaissent une poussée de croissance précoce, généralement à la fin de l'enfance, et ont une petite taille à l'âge adulte. Les femmes atteintes du syndrome présentent rarement des symptômes, mais elles peuvent connaître une croissance mammaire excessive (macromastie), des règles irrégulières et une petite taille. Chez les hommes et les femmes atteints du syndrome d'excès d'aromatase, la capacité à avoir des enfants (fertilité) est normalement normale.

Français Data Bridge Market Research analyse que le marché du syndrome d’excès d’aromatase était évalué à 246,8 millions USD en 2021 et devrait atteindre 378,76 millions USD d’ici 2029, enregistrant un TCAC de 5,50 % au cours de la période de prévision de 2022 à 2029. En plus des informations sur le marché telles que la valeur du marché, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l’équipe de recherche sur le marché Data Bridge comprend également une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Portée du rapport et segmentation du marché

Market Definition

Aromatase excess syndrome (AES or AEXS) is a rare genetic and endocrine syndrome characterized by an overexpression of aromatase, the enzyme responsible for the biosynthesis of the estrogen sex hormones from androgens, resulting in high levels of circulating estrogen and hyperestrogenism symptoms. Treatment must be tailored to each individual. In the case of a tumor, it may include hormone medicines or surgery. The diagnosis of hyperestrogenism is based on a presumptive estrogen test. In a blood or urine sample, an estrogen test analyses the level of each kind of estrogen (estradiol, estriol, and estrone). This reproductive disorder is also termed as familial hyperestrogenism or familial gynecomastia,

Aromatase Excess Syndrome Market Dynamics

Drivers

• Rise in the number of cases of aromatase excess syndrome

The surging number of cases of aromatase excess syndrome is a major factor driving the market's growth rate during the forecast period of 2022-2029. A gain of function mutation in the aromatase gene causes AES, which is an uncommon condition. There have been reports of sub-chromosomal recombination arrangements such as tandem duplications, deletion, and inversion. In males, AES is defined by estrogen excess that begins before or during puberty. Advanced bone ageing and, as a result, short adult height are further signs. Along with this, the rising prevalence of obesity, liver cirrhosis, various types of cancer and hyperplasia will further increase the risk of aromatase excess syndrome and propel the market’s growth rate.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of aromatase excess syndrome market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, rising government initiatives to spread awareness and sedentary lifestyle of people will result in the expansion of aromatase excess syndrome market. Along with this, favourable reimbursement policies will enhance the growth rate of the market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the aromatase excess syndrome market growth.

Moreover, the market's growth is fueled by rising technological advancement in diagnostic methods and emerging new markets. These factors will provide beneficial opportunities for the aromatase excess syndrome market growth.

Restraints/Challenges

On the other hand, high cost associated with the treatment as well as diagnosis will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the aromatase excess syndrome market. Additionally, lack of awareness among people and unfavourable healthcare policies will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This aromatase excess syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the aromatase excess syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Aromatase excess syndrome market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Global Aromatase Excess Syndrome Market Scope

The aromatase excess syndrome market is segmented on the basis of diagnosis, treatment, route of administration, age of onset, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis

• Estrogen Test
• Others

Treatment

• Surgery
• Hormone Medications
• Others

Age of Onset

• Childhood
• Adolescent

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Aromatase Excess Syndrome Market Regional Analysis/Insights

The aromatase excess syndrome market is analysed and market size insights and trends are provided by country, diagnosis, treatment, route of administration, age of onset, end-users and distribution channel as referenced above.

The countries covered in the aromatase excess syndrome market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the aromatase excess syndrome market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing prevalence of aromatase excess syndrome and rising healthcare expenditure will further propel the market’s growth rate in this region. Additionally, growing presence of major key players will further propel the market’s growth rate in this region.

Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to development of healthcare infrastructure in this region. Also, rising government initiatives will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Aromatase Excess Syndrome Market Share Analysis

The aromatase excess syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to aromatase excess syndrome market.

Some of the major players operating in the aromatase excess syndrome market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis SA (Suisse)
• Bayer AG (Allemagne)
• Eli Lilly and Company (États-Unis)
• Merck & Co., Inc. (États-Unis)
• Allergan (Irlande)
• Abbott (États-Unis)
• Merck KGaA (Allemagne)
• Novo Nordisk A/S (Danemark)
• Genentech Inc. (États-Unis)
• Amgen Inc. (États-Unis)
• Endo International plc (Irlande)
• Hisamitsu Pharmaceutical Co., Inc. (Japon)

SKU-68487